Toronto (June 4, 2018) — Borden Ladner Gervais (BLG) releases the fifth annual edition of its report Life Sciences Legal Trends in Canada (LifeSigns). The report features key insights from its Life Sciences team, as well as messages from Canada's leading national and regional life sciences associations.
BLG's LifeSigns report covers notable trends in the areas of Intellectual Property, Regulatory Affairs, Privacy and Cybersecurity, as well as Capital Markets, and includes articles on topics such as patented medecine, NOC Regulations, cannabis, personal information security breach obligations and class actions.
"With 12 representatives attending this year's BIO International Convention in Boston, BLG's Life Sciences Group looks forward to engaging in a meaningful discussion with industry leaders on these significant issues," said Jeffrey Graham, national leader of BLG's Life Sciences Group.
BLG's life sciences practice extends from bench top to boardroom, providing strategic advice to clients across the spectrum of the sector. The firm's multi-disciplinary life science group advises entrepreneurs and investors involved in the commercialization of life sciences technologies, as well as domestic and international clients with products in sale, including drugs, medical devices, natural health products, biomaterials, ag-biotech products and well as companies with energy/environmental applications.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
